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Physiologically relevant sources of absorptive intestinal epithelial cells are crucial for
human drug transport studies. Human adenocarcinoma-derived intestinal cell lines, such
as Caco-2, offer conveniences of easy culture maintenance and scalability, but do not fully
recapitulate in vivo intestinal phenotypes. Additional sources of renewable physiologically
relevant human intestinal cells would provide a much needed tool for drug discovery and
intestinal physiology. We compared two alternative sources of human intestinal cells,
commercially available primary human intestinal epithelial cells (hInEpCs) and induced
pluripotent stem cell (iPSC)-derived intestinal cells to Caco-2, for use in in vitro transwell
monolayer intestinal transport assays. To achieve this for iPSC-derived cells, intestinal
organogenesis was adapted to transwell differentiation. Intestinal cells were assessed
by marker expression through immunocytochemical and mRNA expression analyses,
monolayer integrity through Transepithelial Electrical Resistance (TEER) measurements
and molecule permeability, and functionality by taking advantage the well-characterized
intestinal transport mechanisms. In most cases, marker expression for primary hInEpCs
and iPSC-derived cells appeared to be as good as or better than Caco-2. Furthermore,
transwell monolayers exhibited high TEERwith low permeability. Primary hInEpCs showed
molecule efflux indicative of P-glycoprotein (Pgp) transport. Primary hInEpCs and iPSC-
derived cells also showed neonatal Fc receptor-dependent binding of immunoglobulin
G variants. Primary hInEpCs and iPSC-derived intestinal cells exhibit expected marker
expression and demonstrate basic functional monolayer formation, similar to or better
than Caco-2. These cells could offer an alternative source of human intestinal cells for
understanding normal intestinal epithelial physiology and drug transport.
Keywords: human intestinal epithelial cell (hInEpC), induced pluripotent stem cell (iPSC), permeability,
Transepithelial Electrical Resistance (TEER), neonatal Fc receptor (FcRn)
INTRODUCTION
The use of in vitro cell models for human drug transport studies
has focused on intestinal epithelial cells, as these cultures con-
tain primarily absorptive cells. While isolated human intestinal
epithelial cells (hInEpCs) retain important in vivo anatomical and
biochemical features, they are difficult to culture and have limited
viability. As a result, immortalized human adenocarcinoma cell
lines have been extensively used to study absorption mechanisms.
While immortalized cells offer many advantages, extrapolation
of data generated with these cell lines to in vivo conditions is
often difficult, as these cells originated from tumors and are there-
fore not representative of the true physiological environment (Le
Ferrec et al., 2001). In addition, these cells form monolayers that
are widely used for small molecule intestinal permeation in vitro
studies (below). But, with increasing numbers of biotechnology
protein therapeutics and novel scaffolds available, which open
the possibility for oral delivery, there is a need for alternatives
that more closely recapitulate the physiology of the intestinal
epithelial cell.
The human colorectal adenocarcinoma cell line Caco-2 is fre-
quently used for drug absorption studies, particularly in the
context of small molecules (Le Ferrec et al., 2001; Balimane and
Chong, 2005). Caco-2 cells are easy to culture and have the
capacity to spontaneously differentiate into cells possessing the
morphology and function of enterocytes, the absorptive cells of
the intestine (Balimane and Chong, 2005). Caco-2 cells are com-
monly cultured on semi-permeable inserts in a transwell format,
where the cells form a polarized monolayer (Leonard et al., 2000;
Le Ferrec et al., 2001), and the transport of molecules between
the apical and basolateral chambers can be easily evaluated.While
Caco-2 cells are a good model for observation of passive transcel-
lular and paracellular permeability (Balimane and Chong, 2005),
there are differences in cytokine production and cytokine recep-
tor expression between Caco-2 cells and normal epithelial cells
(Aldhous et al., 2001). In addition, Caco-2 cells under-express
transporters and metabolizing enzymes relative to in vivo tissue,
potentially excluding mechanisms crucial for drug absorption
studies (Balimane and Chong, 2005).
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Due to the limitations of immortalized intestinal cell lines,
many studies have focused on the use of primary hInEpCs
as a more physiologically relevant cell-based model (Perreault
and Beaulieu, 1998; Aldhous et al., 2001; Ootani et al., 2009;
Lahar et al., 2011). However, stocks of these cells are difficult
to maintain due to limited donors and low viability in culture.
Recently, commercial sources of primary hInEpCs were made
available (Lonza; Walkersville, MD), which greatly increase the
convenience of obtaining primary cell stocks. Commercial qual-
ity control data suggest that these primary hInEpCs have the
capacity to form monolayers with tight junctions and express
general epithelial markers, such as cytokeratins 8 and 18 (Bosch
et al., 1988); however, little characterization has be done on
their expression of intestinal cell type-specific markers or trans-
port function. Other efforts to enable long-term culture of pri-
mary cells and enhance physiological conditions have led to
the development of 3-dimensional (3D) models of the intesti-
nal epithelium, which have focused on the use of primary
intestinal stem cells and directed differentiation of pluripotent
stem cells.
Stem cells have the capacity to self-renew and differenti-
ate into the various cell lineages that make up specific tissue
types. For example, intestinal stem cells are responsible for
the self-renewal of the gut epithelium, and have been used in
developing 3D intestinal models. Leucine-rich repeat-containing
G protein-coupled receptor 5 (LGR-5)-positive stem cells can
be isolated from primary intestinal tissue and grown as 3D
intestinal organoids with crypt-villius physiology and cultur-
ing capacity up to 8 months (Sato et al., 2009). While 3D
organoids derived from primary intestinal stem cells appear
to possess physiologically relevant phenotypes, they cannot be
used to assess classical functionality typically determined within
2-dimensional transwell cultures, such as the formation of
monolayers with tight junctions and intestinal permeability and
transport.
An additional source of human intestinal cells is possible
through directed differentiation of pluripotent stem cells to
intestinal cell lineages. The recent advent of human induced
pluripotent stem cells (iPSCs) has provided a huge thera-
peutic potential as a tool for drug discovery, as patient-
specific somatic cells can be reprogrammed into an embry-
onic stem cell-like state that can be directly differentiated to
a specific cell type of interest for more physiologically rel-
evant disease modeling. Induced human intestinal organoids
(iHIOs) have recently been derived from iPSCs (Spence et al.,
2010), which are capable of expressing epithelial and intesti-
nal markers such as caudal type homeobox 2 (CDX2) (hindgut
marker), E-Cadherin (cell-to-cell junction marker), and Villin
(epithelial brush border marker). However, to our knowl-
edge, the methods for differentiating these into a polar-
ized epithelial monolayer similar to Caco-2 have not been
reported.
In this study, we assessed expression of markers and functional
activity of the newly commercially available primary hInEpCs and
iPSC-derived intestinal cells compared to Caco-2 (Figure 1) in
cell-based in vitro assays. We adapted our previously described
3D intestinal organogenesis to differentiation within transwells.
Intestinal marker expression, formation of monolayers with tight
junction formation and functional molecule transport and bind-
ing were evaluated.
MATERIALS AND METHODS
CELL CULTURE
Intestinal cells
Human primary small intestinal epithelial cells (Lonza;
Walkersville, MD) from 3 donors (Donor A: Lot # 0000258132;
Donor B: Lot # 0000256741; Donor C: Lot # 0000256744) were
thawed and cultured in transwell inserts for 10–11 days in
SmGM-2 media (Lonza), according to manufacturer’s instruc-
tions. Caco-2 colorectal adenocarinoma-derived cells (ATCC;
Manassas, VA) were cultured in transwell inserts for 14–21 days
in Caco-2 media (10% fetal bovine serum, 1X non-essential
amino acids, 1X sodium pyruvate, and 6mM L-Glutamine in
Dulbecco’s Modified Eagle’s Medium (DMEM) High Glucose,
reagents from Life Technologies; Carlsbad, CA).
iPSCs
A1145A and B2198A (Johnson & Johnson; Spring House, PA)
were produced from human kidney-derived cells using retro-
viral (Takahashi et al., 2007) and modified mRNA (non-viral)
reprogramming methods (Yakubov et al., 2010), respectively.
C2198A and C2200B (Johnson & Johnson; Spring House,
PA) were produced from human umbilical tissue-derived cells
by modified RNA reprogramming methods. D2043A (System
Biosciences; Mountain View, CA) was derived from human fore-
skin fibroblasts by retroviral methods. iPSC lines were main-
tained in mTeSR1 culture media (STEMCELL Technologies;
Vancouver, BC) on culture dishes/flasks coated with Geltrex
(Life Technologies) and passaged by Dispase (STEMCELL
Technologies) dissociation every 3–5 days as previously described
(McCracken et al., 2011).
iPSC DIRECTED DIFFERENTIATION
Transwell differentiation
Semi-permeable transwell inserts were coated apically with
Geltrex (Life Technologies) prior to plating iPSCs within 12-
well transwell tissue culture plates. iPSCs were plated apically
as cell clumps (5–10 cells per clump) at a density of 3000–6000
clumps per transwell insert. Two to three days after plating, iPSCs
were differentiated within transwell inserts modified previously
reported methods (Spence et al., 2010) into definitive endoderm
using GDF8 with GSK3b inhibitor and B27 supplement then
differentiated to hindgut using Keratinocyte Growth Factor and
Retinoic Acid then EGF, Noggin, and R-Spondin1 for >26 days
(Kauffman et al., Submitted) on both sides of the transwell insert;
however, the many spheroid structures observed at Stage 2 were
maintained as part of the adherent layer throughout Stage 3
differentiation (Table 1) for up to 31 days.
MONOLAYER ASSESSMENT
Transepithelial electrical resistance (TEER)
TEER of transwell cultures was recorded in measurements of
Ohms using an Epithelial Volt Ohm Meter (EVOM)2 and
electrode set (World Precision Instruments; Sarasota, FL). Raw
Frontiers in Pharmacology | Gastrointestinal Pharmacology July 2013 | Volume 4 | Article 79 | 2
Kauffman et al. Alternative human intestinal epithelial models
FIGURE 1 | Overview of isolation and utilization of human intestinal epithelial cells in transwell cultures for in vitro assays. Major sources of human
intestinal cells include intestinal carcinoma tissue, normal intestinal tissue, or directed differentiation of induced pluripotent stem cells.
Table 1 | Summary of growth factors and differentiation cell culture conditions used for transwell differentiation, relative to previously
established intestinal organogenesis to 3D organoids.
Stage Growth factors Days Cell type Stage markers Organoid culture Transwell culture
1 GDF-8, GSKi, B27 3 Definitive endoderm SOX17, CXCR4 2D Standard tissue culture
plate
2D Transwell
2 KGF, RA 7 Hindgut CDX2 2D Excise spheroids from
standard plate
2D Transwell (No Spheroid
Excision)
3 EGF, Noggin, R-Spondin1 26+ Intestinal E-Cad, CDX2, Villin 3D Intestinal matrigel 2D Transwell
data was converted to  × cm2 based on area of transwell plate
inserts (1.12 cm2).
FITC-dextran permeability
Cells in 24-well transwell plates were washed twice with DPBS
(Life Technologies). To the apical side, 200μ L of 12.5mg/mL
Fluorescein isothiocyanate–dextran, molecular weight 150 kDa
(FD150) (Sigma–Aldrich) diluted in Caco-2 media (pH = 6.0)
was. To the basolateral side, 500 uL of Caco-2 media (pH = 7.4)
was added. After a 90-min incubation at 37◦C, 100 uL of media
was collected from the basolateral chamber and analyzed for the
presence of FITC-Dextran using a SpectraMax M5 microplate
reader (Molecular Devices; Sunnyvale, CA).
P-GLYCOPROTEIN TRANSPORT ASSAY
Primary hInEpCs were dosed on the apical or basolateral side
with a 2mM mix of Digoxin and Atenolol in HBSSg [2mM glu-
cose and 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid in Hank’s Balanced Salt Solution (HBSS)] with calcium and
magnesium, pH = 7.4) and incubated for 90min at 37◦C in the
presence or absence of 10μMCyclosporin A (CSA). Samples were
collected from both the apical/donor and basolateral/receiver
chambers and analyzed by LCMS. Digoxin and Atenolol levels
in each condition were used to calculate apparent permeability
(Papp = δCr/δt) × Vr / (A × C0)) in the apical to basolat-
eral (A–B) or basolateral to apical (B–A) direction. δCr = final
receiver concentration; δt = assay time; Vr = receiver volume;
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A = transwell growth area; C0 = initial apical concentration.
To ensure monolayer integrity during the assay, all wells were
dosed apically with 100μ g/mL Lucifer Yellow (LY) at the start
of Digoxin and Atenolol incubation, and samples were collected
from the basolateral chamber for analysis by SpectraMax M5
microplate reader at the end of the 90min incubation. Only tran-
swells with a LY Papp(A–B) of < 1 × 10−6 cm/s were used in
calculating final Papp Ratios for Digoxin and Atenolol. Based
on this cutoff, one of 8 wells each for hInEpC Donors A and
B, and two of 8 wells for Donor C was excluded from data
analysis.
mRNA EXPRESSION
RNA was harvested from Caco-2, primary hInEpCs, or iPSCs
before or after differentiation to Stage 3 by RNeasy Mini
kit (Qiagen; Germantown, MD), and reverse transcribed
to cDNA using the RT2 First Strand kit (Qiagen). Using
30 ng/μL starting cDNA, samples were used in reactions
within Custom RT2 Profiler PCR array containing probes
supplied by the manufacturer (SABiosciences; Valencia, CA)
for intestinal and control markers (Table 2), following reac-
tion cycling conditions outlined in the manufacturer’s proto-
col. Data analysis was performed using the  CT method,
where raw Ct values were normalized to housekeeping gene
60S acidic ribosomal protein P0 (RPLP0) before comparing
expression relative to Caco-2. Expression levels for primary
hInEpCs represents the average across all three donors used in
this study.
Table 2 | List of probes used in Custom RT2 Profiler PCR array mRNA
expression analyses of intestinal and control markers in intestinal
epithelial cells.
Gene NCBI reference no SAB catalog no
E-Cadherin NM_004360 PPH00135
CDX2 NM_001265 PPH13618
KLF5 NM_001730 PPH00434
Villin NM_007127 PPH23365
SOX9 NM_000346 PPH02125
LGR5 NM_003667 PPH13346
ASCL2 NM_005170 PPH12852
MUC2 NM_002457 PPH06990
Chromogranin A NM_001275 PPH01181
LYZ NM_000239 PPH14748
VIM NM_003380 PPH00417
FcRn NM_004107 PPH11194
CXCR4 NM_003467 PPH00621
PDX1 NM_000209 PPH05536
OCT4 NM_002701 PPH02394
TNNT2 NM_000364 PPH02619
PAX6 NM_000280 PPH02598
TUBB3 NM_006086 PPH02607
RPLP0 NM_001002 PPH21138
Probes for the NCBI Reference sequence numbers listed were obtained from
SABiosciences (SAB) using the catalog numbers provided.
PROTEIN EXPRESSION
Flow cytometry
Undifferentiated or Stage 1 iPSCs were detached by treatment
with Accutase (Sigma-Aldrich; St. Louis, MO) and stained for
viability by Near Infrared Live/Dead kit (Invitrogen; Carlsbad,
CA) before fixation in Cytofix Buffer (BD Biosciences; San Jose,
CA). For pluripotent marker analyses, cells were stained using
Human Pluripotent Stem Cell Transcription Factor Analysis or
Human Pluripotent Stem Cell Sorting and Analysis kits (BD
Biosciences). For definitive endoderm marker analysis, cells were
stained with a 1:5 dilution of PE-conjugated mouse anti-human
CD184/ C-X-C chemokine receptor type 4 (CXCR4) (306506,
Biolegend; San Diego, CA) before permeabilized with Phosflow
Perm Buffer (BD Biosciences) and stained with a 1:5 dilu-
tion of APC-conjugated goat polyclonal anti-human Sry-related
HMG box 17 (SOX17) (IC1924A, R&D Systems; Minneapolis,
MN). For analysis of surface expression of neonatal Fc recep-
tor (FcRn), Caco-2 and primary hInEpCs were dissociated from
transwell culture by Accutase, incubated with 50μg/mL affin-
ity purified rat anti-human FcRn polyclonal antibody (gener-
ated in house), followed by incubation with 7.5μg/mL FITC
Donkey anti-rat IgG (FAb2) secondary antibody (109-006-
006, Jackson Immunoresearch; West Grove, PA). Fluorescence
of stained cells was measured in conjunction with appropri-
ate compensation controls (BD Biosciences) by flow cytometry
using an LSR Fortessa FACS Sorter (BD Biosciences). Raw data
was analyzed by FlowJo analysis software (Tree Star; Ashland,
OR), with gating parameters set based on isotype controls
(Figure A1A).
Immunofluorescence
iPSC-derived cells Stage 2 iPSC-derived cells were fixed in
4% paraformaldehyde (Electron Microscoopy Sciences; Hatfield,
PA) before permeabilization with 0.5% Triton X-100 (Electron
Microscoopy Sciences). After addition of Image-iT® FX sig-
nal enhancer (Invitrogen), cells were treated with 1X Blocking
Buffer (Sigma) before exposure to a 1:50 dilution of E-
Cadherin, CDX2, or Villin antibodies (Dako), using manufac-
turer recommended concentrations. Immunoreactivity to pri-
mary antibodies was detected with a 1:500 dilution of AF568-
conjucated goat anti-mouse antibody (Invitrogen). Prolong
GOLD antifade with DAPI (Invitrogen) was added to wells prior
to visualizing on a Nikon SMZ-1500 fluorescence dissecting
microscope.
FcRn-DEPENDENT IMMUNOGLOBULIN G (IgG) BINDING
Caco-2, hInEpCs (Donor A), or iPSC-derived cells were detached
from transwells by Accutase (Sigma) treatment and washed
twice with Dulbecco’s Phosphate-Buffered Saline (DPBS) (Life
Technologies). Cells were transferred in DPBS to MesoScale
Discovery (MSD) High Bind plates (MSD; Rockville, MD) at a
density of 1 × 104 or 2.5 × 104 cells per well, and incubated at
room temperature for 2 h to allow attachment to the plate sur-
face. Plates were then blocked with 20% Fetal Bovine Serum (Life
Technologies) and 0.18% Sodium Azide (VWR International;
Radnor, PA) for 15min at room temperature. Wells were washed
once with DPBS at pH 6.0 before incubation with FcRn-binding
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variants (anti-RSV N434A or anti-RSV H435A in DPBS at pH
6.0) for 90min at 37◦C. Plates were washed 3 times with DPBS
at pH 6.0, and cells were incubated with ruthenium-labeled
goat anti-human IgG F(ab’)2 (1μg/ml in DPBS at pH 6.0)
for 1 h at room temperature. Cells were washed 3 times with
DPBS at pH 6.0. Tris-based Read Buffer T without surfactant
(MSD) was added to wells immediately before measuring Relative
Luminscent Units (RLU) using a Sector Imager 6000 reader
and Discovery Workbench software (MSD). For analysis, back-
ground signal RLUs were subtracted from RLUs of samples run in
triplicate.
RESULTS
MULTIPLE SOURCES OF HUMAN INTESTINAL EPITHELIAL CELLS
EXHIBIT INTESTINAL MARKER EXPRESSION
Along with limited viability in culture, one of the major draw-
backs of routinely using primary hInEpCs for studying intestinal
physiology is that these cells must be collected from human
donors. A newly available commercial source of primary hInEpCs
greatly increases the convenience of obtaining primary cell stocks,
but need to be further characterized for intestinal cell-type spe-
cific marker expression and functional monolayer formation.
Thus, we sought to characterize these commercially available
stocks to assess their physiological relevance for use in cell-based
in vitro assays of intestinal uptake and transport.
As previously reported, a measure of intestinal cell phenotypic
quality is the expression of a panel of general intestinal epithe-
lial markers (Spence et al., 2010). We used immunocytochemistry
to verify expression and expected localization of several represen-
tative intestinal epithelial markers within primary hInEpCs from
three different donors (Figure 2, top row; Figure A1B), relative
to the immortalized human intestinal epithelial cell line Caco-2
(Figure 2, bottom row). This was visualized for E-cadherin, an
epithelial cell adhesion marker found within tight junctions
between cells (Zbar et al., 2004), CDX2, a transcription factor that
is upstream of signaling promoting intestinal cell fate (Gao et al.,
2009) and Villin, an actin-binding protein associated with the
intestinal brush border of absorptive enterocytes (Friederich et al.,
1999). The localization of these markers within cells was appro-
priate in primary hInEpCs and Caco-2 (Figure 2). Marker expres-
sion intensity was variable between the three hInEpC donors
within this study, with strongest expression evident in Donor A
(Figure 2, top row; Figure A1B). Expression results for hInEpCs
and Caco-2 were used to compare to iPSC-derived iHIOs grown
in transwells (below).
In order to evaluate iPSC-derived intestinal cell phenotypes
within classical in vitromonolayer conditions, we adapted intesti-
nal organogenesis to transwell culture by performing iPSC dif-
ferentiation through Stage 3 within transwell inserts (Table 2,
Figure 3A). Differentiation of a panel of iPSC lines (A1145A,
B2198A, C2128A, C2200B, and D2043A) on matrigel-coated
transwell inserts using Myostatin, Glycogen Synthase Kinase
3β inhibitor and B27 supplement resulted in cells expressing
definitive endoderm markers SOX17 and CXCR4 (Figure 3B),
similar to iPSCs differentiated to Stage 1 in standard tissue
culture plates (Kauffman et al., Submitted). Further differentia-
tion of iPSC-derived definitive endoderm cells within transwell
plates, by addition of Keratinocyte Growth Factor and Retinoic
Acid, produced layers of cells with developing spheroid struc-
tures at Stage 2 in many of the iPSC lines (Figure 3C, top
row). CDX2 expression at Stage 2 was relatively uniform within
layers of cells differentiating in transwells (Figure 3C, bottom
row). However, D2043A showed more intense expression around
spheroid structures.
FIGURE 2 | Characterization of intestinal marker expression in
commercially available (Lonza) primary human intestinal epithelial cells
(hInEpCs) relative to immortalized human intestinal cell line Caco-2. Top
row: primary hInEpCs uniformly express intestinal epithelial markers
E-Cadherin (tight junctions), CDX2 (hindgut), and Villin (enterocytes). Primary
hInEpC Donor A shown (see Figure A1B for Donors B and C). Bottom row:
Caco-2 show less uniform expression of enterocyte marker Villin. Scale bar,
100μm.
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FIGURE 3 | iPSC directed intestinal differentiation in transwell culture
results in cells with expected morphology and marker expression
through Stage 2. (A) Directed intestinal differentiation occurs through
several distinct stages. (B) Transwell cells derived from a panel of iPSC
lines express Definitive Endoderm markers SOX17 and CXCR4 at
Stage 1. (C) Top row: transwell iPSC panel morphology at Stage 2
differs in amount and size of budding spheroids (arrow heads). Scale
bar, 250μm. Bottom row: CDX2 expression of Stage 2 transwell
iPSC-derived cells differs among cell lines in intensity and uniformity.
Scale bar, 250μm.
iPSC-derived Stage 3 3D intestinal organoids exhibit
E-Cadherin, CDX2, Villin, and Chromogranin A immunore-
activity with the expected localization, (Kauffman et al.,
Submitted). In this study, a supply of transwell A1145A iPSC-
derived Stage 3 Day 31 cells was limited, and did not allow
sufficient material for extensive immunocytochemistry analyses
of intestinal markers. Thus, mRNA expression analysis was used
to directly compare larger panel of known intestinal marker
and differentiation control genes Stage 3 A1145A iPSC-derived
intestinal marker expression to Caco-2 and primary hInEpCs
by RT-PCR (Figure 4). Differentiated Stage 3 iPSCs showed
increased marker expression relative to undifferentiated cells,
usually reaching a level more similar to primary hInEpCs in
the case of 3D iHIOs (Figure 4), or more similar to Caco-2 in
the case of transwell-differentiated iPSCs (Figure 4). Intestinal
markers that followed this expression pattern included epithe-
lial tight junction marker E-Cadherin (Zbar et al., 2004),
hindgut epithelial marker CDX2 (Gao et al., 2009), entero-
cyte maker Villin (Friederich et al., 1999), enteroendocrine
marker Chromogranin A (O’Connor et al., 1983), and Mucin-2
(MUC2), a marker for intestinal goblet cells (Gum et al., 1999)
(Figures 4A–E).
For some intestinal makers, expression in iPSC-derived intesti-
nal cell types was highest in iPSC-derived cells. For example,
expression levels of intestinal crypt cell marker Sex determin-
ing region Y-box 9 (SOX9), paneth cell marker Lyzosyme (LYZ)
(Peeters and Vantrappen, 1975), and intestinal stem cell marker
LGR5 (Barker et al., 2007) were greatest in iHIOs and tran-
swell differentiated cells compared to Caco-2 or primary hInEpCs
(Figures 4F–H). On the other hand, an additional intestinal stem
cell marker, Achaete Scute-Like 2 (ASCL2) (van der Flier et al.,
2009), was most highly expressed in Caco-2 (Figure 4I). In the
case of intestinal epithelial cell differentiation transcription factor
Kruppel-like factor 5 (KLF5) (Bell et al., 2013), mRNA expression
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FIGURE 4 | Comparison of intestinal marker mRNA expression in
multiple sources of human intestinal epithelial cells. Expression of
tight junction marker (A) and hindgut epithelia (B), as well as specific
epithelial lineage markers (C–J) intestinal markers of epithelial intestinal
lineages was evaluated by RT-PCR in Caco-2, primary hInEpCs (average
of Donors A–C), and iPSC-derived undifferentiated (Undiff), Stage 3
induced human intestinal organoids (Stg 3 iHIOs), or Stage 3 transwell
intestinal cells (Stg 3 TW). Using the Ct method, raw Ct values were
normalized to housekeeping gene RPLP0. N = 3; Error bars represent
SEM.
www.frontiersin.org July 2013 | Volume 4 | Article 79 | 7
Kauffman et al. Alternative human intestinal epithelial models
levels were similar for all intestinal cell types (Figure 4J). The
expression of several control genes [e.g., pluripotent marker
Octamer-binding Transcription factor 4 (OCT4) (Nichols et al.,
1998)] confirmed the cell sample quality (Figure A3).
PRIMARY hInEpCs AND iPSC-DERIVED INTESTINAL CELLS FORM
TRANSWELL MONOLAYERS WITH TIGHT JUNCTIONS
While all three primary hInEpCs donors appeared to be capa-
ble of forming confluent cell layers in transwell culture that
expression the tight-junction marker E-Cadherin (Figures 2,
4A), we assessed tight junction formation functionally through
measurements of Transepithelial Electrical Resistance (TEER)
and monolayer permeability. As confluent epithelial mono-
layers form, TEER measurements generally increase, reaching
260–420  × cm2 on average in Caco-2 cultures (Le Ferrec
et al., 2001). We found that after 11 days of transwell culture,
primary hInEpCs from all three donors exhibited TEER mea-
surements of > 1500 × cm2 (Figure 5A), providing a strong
indication of tight junction formation. As changes in epithe-
lial TEER can also be explained by changes in transcellular
ion permeability (Yu and Sinko, 1997), we confirmed tight
junction formation of pInEpC transwell cultures by deter-
mining the monolayer permeability to FITC-labeled Dextran
at a molecular weight of 150,000 (FD150). Apical side incu-
bation in transwell chambers, resulted in <3% FITC-labeled
Dextran detected on the basolateral side, relative to control
transwells with no cells for primary hInEpC Donors A and
B (Figure 5B). Donor C, which corresponds to the cells with
highly variable TEER measurements (Figure 5B) showed slightly
more FITC-Dextran permeability (∼3% relative to control tran-
swells).
While Stage 3 Day 31 transwell A1145A iPSC-derived cells
exhibited intestinal marker expression consistent with other
intestinal epithelial cell sources, it was difficult to gauge at which
point during Stage 3 differentiation iPSC-derived cells may begin
to take on functional phenotypes. Thus, we performed a time
course experiment in which A1145A iPSCs were differentiated
within transwell culture and assessed for monolayer morphol-
ogy and evidence of tight junction formation throughout Stage
3 (Days 0, 7, 14, 21, 31). Morphologically, A1145A iPSC-derived
cells showed 3D structures and dense patches of cells within
transwells at the beginning of Stage 3 that appeared to disap-
pear as differentiation progressed, leaving a flat monolayer-like
layer of cells by Day 31 of Stage 3 (Figure 5C). To assess tight
junction formation in confluent A1145A iPSC-derived transwell
monolayers, we measured TEER and FITC-Dextran permeabil-
ity during iPSC transwell differentiation. At Day 0 of Stage
3 differentiation, A1145A iPSC-derived cells within transwells
exhibited low TEER measurements of less than 200  × cm2
which steadily increased to measurements reaching 937  ×
cm2 by Day 31 (Figure 5D). At Stage 3 Day 0, iPSC-derived
cells showed FD150 permeability of ∼2% relative to the no
cell control (Figure 5E), a range similar to that seen for pri-
mary hInEpCs (Figure 5B). Coinciding with changes in TEER
measurements during differentiation (Figure 5D), FD150 perme-
ability decreased for iPSC-derived cells to as low as 0.06% of the
no cell control (Figure 5E).
INITIAL ASSESSMENT OF INTESTINAL EPITHELIAL TRANSPORT
FUNCTION
To further validate these cell sources functionally, we assessed
monolayers for molecule transport or binding. A previously
established mechanism influencing small molecule transport by
intestinal epithelial cells is efflux by membrane associated ATP-
binding cassette P-glycoprotein (Pgp) transporters, which facil-
itate cellular efflux to prevent accumulation of their substrates
(Murakami and Takano, 2008). To assess Pgp transport activity
for a given substrate, the basolateral to apical (B–A) permeabil-
ity is compared to apical to basolateral (A–B), where compounds
with efflux ratios (B–A/A–B) greater than 2 or 3 are generally
considered to be Pgp substrates (Balimane et al., 2006). Using
transwell monolayers of primary hInEpCs, we found that efflux
ratios for Digoxin, a compound known to be highly effluxed by
Pgp (Balimane et al., 2006), were >8 for pInEpC Donors A and
B (Figure 6A). Importantly, efflux of Digoxin was reduced when
these cells were also treated with CSA, a known Pgp transporter
inhibitor (Watanabe et al., 1997). Atenolol, a poorly Pgp-effluxed
compound (Balimane et al., 2006) showed very low efflux ratios
of <1 in all three primary hInEpC donors, which was not fur-
ther reduced by CSA (Figure 6B). During the Pgp transport assay,
transwells were also dosed apically with lucifer yellow to confirm
primary hInEpC monolayer integrity based on permeability of
this fluorescent molecule (Figure A3). While the average appar-
ent permeability for all three primary hInEpC donors was below
1.5 × 10−6 cm/s, only transwells below this standard cutoff were
used for analysis of Digoxin and Atenolol flux.
Unfortunately, as A1145A iPSC-derived transwell intestinal
cells were very limited, there were insufficient cells within this
study to perform a properly-controlled Pgp transport assay.
Thus, to further validate iPSC-derived cells, we assessed FcRn
immunoreactivity and performed a cell surface binding assay
for neonatal Fc receptor (FcRn)-mediated transport, which was
amenable to the limited cell supply.
Intense FcRn expression in iPSC-derived intestinal organoids
was noted as intense single-cell expression within the popula-
tion of cells (Figure A4A) similar that previously reported for
human intestinal tissue (Dickinson et al., 1999). We confirmed
FcRn expression immunocytochemically in transwell monolayer
cultures of Caco-2 and primary hInEpCs both intracellularly
(Figure 6C) and on the surface of cells (Figure A4B). Real-Time
RT-PCR analysis showed that FcRn mRNA expression increases
to the level close to that of Caco-2 by Stage 3 of transwell dif-
ferentiation (Figure 6D), whereas FcRn expression was highest in
primary hInEpCs and iHIOs.
We examined binding of high or low FcRn-binding IgG mAb
variants to Caco-2, primary hInEpCs, or iPSC-derived transwell
intestinal cells by Meso Scale Discovery assay. Use of this highly
sensitive ELISA-like assay allowed us to perform FcRn-dependent
binding experiments with proper controls, even with limited-
supply iPSC-derived cells. Similar to Caco-2, primary hInEpCs
showed significantly higher binding of the IgG variant with a
high affinity to FcRn (N434A) than the low FcRn-binding variant
(H435A) (Figure 6E). iPSC-derived intestinal cells also demon-
strated significantly higher binding of a high FcRn-binding
IgG variant (M428L) relative to the low FcRn-binding variant
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FIGURE 5 | Primary hInEpCs and iPSC-derived cells develop transwell
monolayers with comparable integrity. (A) Primary hInEpC
monolayers exhibited Transepithelial Electrical Resistance measurements
of > 1500 × cm2. (B) All primary hInEpC donors exhibit FITC-Dextran,
molecular weight 150 kDa (FD150) permeability below 3%, relative to no
cell control. (C) A1145A-derived cells lose dense structures during
transwell differentiation in Stage 3 media, leaving behind confluent
monolayer-like cells by Day 31. Scale bar, 250μm. (D) Differentiating
iPSCs (cell line A1145A shown) are capable of exhibiting increasing
TEER during Stage 3 differentiation, reaching > 900 × cm2 by Day 31.
(E) A1145A cells exhibit low FD150 permeability with increasing days in
Stage 3 culture relative to no-cell control. N ≥ 3; Error bars represent
SEM. For panels (A) and (B), significance was determined by One-Way
ANOVA, ∗p < 0.01.
(H435A), however, maximal cell binding was not as high as
Caco-2 (Figure 6F).
DISCUSSION
The major findings of this study are that marker expression of
primary hInEpCs and iPSC-derived intestinal cells were on the
same order of magnitude, or better than Caco-2, as determined
by immunocytochemistry and mRNA expression analyses. The
iPSC-derived intestinal cells were successfully adapted to dif-
ferentiation within 2D transwell monolayer culture, and sim-
ilar to primary hInEpCs, demonstrated functional tight junc-
tions with TEER and low permeability similar to, or better
than, Caco-2. Initial assessment suggested functional activity for
intestinal transporters such as Pgp transport (primary hInEpCs)
or FcRn-dependent binding of molecules (primary hInEpC and
iPSC-derived cells). The main conclusions from our study are
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FIGURE 6 | Primary hInEpCs and iPSC-derived intestinal monolayers
show functional activity in transwell culture. (A) pInEpC donors A and B
show Digoxin Papp Ratios >8, which are decreased in the presence of
cyclosporin A (CSA), suggesting that these cell lines have P-glycoprotein
(Pgp) transport activity. (B) Atenolol Papp ratios for all samples fell below the
expected <2 cutoff for Pgp activity. (C) Primary hInEpCs (right) show more
uniform intracellular FcRn expression than Caco-2 (left), as shown by
immunofluorescence. Scale bar, 100μm. (D) iPSC-derived transwell cells
express FcRn mRNA levels similar to Caco-2, but lower than primary hInEpCs
and iPSC-derived 3D induced human intestinal organoids (iHIOs). Caco-2
(E,F), primary hInEpCs (E) and iPSC-derived transwell cells (F) show
FcRn-dependent mAb binding by MSD assay, as demonstrated by statistically
greater cell binding of high FcRn-binding IgG variants [High, N434A (E) or
M428L (F)] than low FcRn-binding variants (Low, H435A). N ≥ 4; Error bars
represent SEM. (E,F), statistical significance determined by t-test,
∗p < 0.001.
further discussed below in relation to previously published
studies.
Before using a recently released commercially available source
of primary hInEpCs for comparing iPSC-derived intestinal
cells, it was necessary to more fully characterize this intesti-
nal epithelial cell source for marker expression and barrier
function. The extent to which primary hInEpCs expressed
markers by immunofluorescence varied, with expression of
E-Cadherin, Villin, and CDX2 strongest in Donor A; how-
ever, intestinal marker expression appeared to be more con-
sistent between donors by RT-PCR analysis. While all three
donors exhibited high TEER (> 1500 × cm2), TEER and
FD150 permeability showed high variability in Donor C.
Moreover, Donor C showed poor efflux of Pgp-transported
Digoxin, suggesting that this primary hInEpC donor is less use-
ful for intestinal barrier function and transport than Donors
A and B.
A 3D directed intestinal organogenesis protocol was success-
fully adapted to 2D transwell differentiation, based on intestinal
marker similarity. Stage 1/Definitive endoderm markers SOX17
and CXCR4 were expressed in 40–87% of the cell popula-
tion. Stage 2-marker CDX2 was also robustly expressed within
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transwell cultures. Stage 3 differentiation within transwells of
iPSC-line A1145A (Kauffman et al., Submitted) was similar
to the development of iHIOs, except that spheroid structures
that formed by Stage 2 of differentiation were not excised for
3D culture, but allowed to continue differentiation within the
adherent layer of cells. Interestingly, spheroid structures found
at Stage 2 were gradually lost, so that by Stage 3, Day 31,
a monolayer-like morphology was found within transwell cul-
tures, which showed TEER measurements more similar to pri-
mary hInEpCs and greater than the average TEER for Caco-2
transwell cultures (Le Ferrec et al., 2001). Consistent with
this result, low permeability of FD150 for primary hInEpCs
and iPSC-derived transwell cells suggests that a barrier func-
tion was present in these cell cultures. It is important to
note that the TEER obtained in this study for human intesti-
nal epithelial cell sources is several-fold higher than typically
found in intestinal tissue ex vivo; however, high TEER val-
ues may not discount the physiological relevance of these cells
in vitro, as the presence of several epithelial layers and cell
types within intestinal tissue can add multiple impedances to
intestinal transmural TEER measurements (Gitter et al., 1998,
2000).
In addition to A1145A, which shows consistent robust intesti-
nal differentiation in 3D and 2D monolayer culture, we also
performed a transwell differentiation time course on C2128A
because this cell line showed uniform expression of CDX2
at Stage 2 within transwell culture, but demonstrated a dis-
tinct morphology. At Stage 2, C2128A cells appeared to already
exhibit a monolayer-like morphology with little to no dense
structures; therefore, we reasoned that C2128A might be more
amenable to the development of iPSC-derived intestinal cells
for use in functional transwell monolayer assays. However,
as Stage 3 differentiation of C2128A-derived progressed, holes
appeared within the layer of cells, which corresponded to low
TEER measurements and high FD150 permeability at Stage 3
(Figure A5). Thus, differences in iPSC line intestinal differenti-
ation capacity appear to be evident during 2D transwell culture
differentiation.
mRNA expression analysis of an extensive panel of intestinal
marker and control genes enabled a direct comparison of pri-
mary hInEpCs and iPSC-derived cell maker expression to Caco-2
cells. As expected, undifferentiated iPSCs showed levels of marker
expression several fold lower than all intestinal samples with the
exception of the pluripotent cell control marker OCT4 (Nichols
et al., 1998). Differentiated iPSC-derived iHIOs and transwell
cells exhibited upregulated intestinal marker expression that was
more similar to primary hInEpCs than Caco-2, consistent with a
better in vitro representation of human intestinal epithelia than
Caco-2.
As might be expected, expression of definitive endoderm
marker CXCR4 was highest in Stage 3 iHIOs and transwell cells,
which went through a definitive endoderm intermediate at Stage
1. Similarly, expression of the mesenchymal marker Vimentin
was also most highly upregulated in iPSC-derived intestinal
cells, relative to Caco-2. This result is consistent with previously
reported increases in expression of Vimentin and another mes-
enchymal marker, Forkhead Box F1 (Mahlapuu et al., 1998), in
intestinal cells derived from human embryonic stem cells, any
may indicate the development of intestinal subepithelial myofi-
broblasts (Spence et al., 2010).
The intestinal stem cell marker LGR-5 (Barker et al., 2007)
was highly upregulated in iPSC-derived intestinal cells relative
to Caco-2, which may reflect more active intestinal cell prolif-
eration within these cells, particularly in iHIOs. Expression of
Paired Box Gene 6 (PAX6), with known roles in brain develop-
ment (Mastick et al., 1997), was also highly expressed in iHIOs
cells, with less expression in Stage 3 iPSC-derived transwell cells
or the other intestinal sources tested. This is consistent with the
high Chromogranin A expression in the development of a more
mature enteroendocrine system within these cells, as PAX6 also
has a known role in the development of Glucagon-like peptide
(GLP)-1 and GLP-2 secreting cells (Fujita et al., 2008; Ye and
Kaestner, 2009).
While intestinal marker expression in primary of iPSC-derived
cells was very encouraging, it was unclear how functional these
cells are compared to other established in vitro intestinal mod-
els, such as Caco-2 or primary tissue. For example, in pluripotent
stem-cell derived models of liver or pancreas, progenitor cells
must be engrafted into whole animals to produce mature, fully-
functional cell types (Liu et al., 2011; Rezania et al., 2011).
We realized that adaptation of directed intestinal organogen-
esis to 2D transwell culture would allow a more direct com-
parison of iPSC-derived intestinal cell barrier and transport
functions to previously characterized intestinal epithelial cell
models in vitro. Well-studied intestinal transport mechanisms
within Caco-2 and primary human intestinal tissue include efflux
of small molecules by membrane associated Pgp transporters,
(Murakami and Takano, 2008), and intestinal receptor-mediated
antibody transcytosis by FcRn (Dickinson et al., 1999; Claypool
et al., 2004). These mechanisms were used as an initial assess-
ment of functional quality of primary hInEpCs and iPSC-derived
intestinal cells.
Primary hInEpCs A and B showed cyclosporine A-dependent
efflux of Digoxin, but not Atenolol, indicative of the presence
of Pgp transport activity in these cells. In addition to primary
hInEpCs (Donor A), Stage 3 iPSC-derived transwell cells showed
FcRn expression and FcRn-dependent mAb binding using high
or low FcRn-binding IgG variants; however, unlike primary
hInEpCs, iPSC-derived IgG binding did not occur to as large
an extent as Caco-2. It should also be noted that in all FcRn-
binding experiments, the cell binding signal, while well above
background noise, was relatively low for this ELISA-based assay.
Furthermore, since FcRn is expressed in neonatal and adult
intestinal epithelial cells in primates (Israel et al., 1997; Dickinson
et al., 1999) and marker expression during differentiation of
iHIOs closely resembles that of embryonic intestinal development
(Spence et al., 2010), it is still unclear whether the phenotype of
these cells more closely resembles embryonic or adult intestinal
tissue.
In summary, our studies indicate that iPSC-derived intesti-
nal cells and newly commercially available primary hInEpCs
may provide an alternative source of physiologically rele-
vant hInEpCs. Future studies will be needed to further eval-
uate the function of primary hInEpCs and iPSC-derived
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intestinal cells. Additionally, as these cells are still limited by their
viability (hInEpCs) and extensive differentiation time (iPSC-
derived cells), large-scale studies will require additional devel-
opment of methods for scale up or long-term maintenance of
these transwell cultures, such as non-oncogenic immortalization
strategies.
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APPENDIX
RESULTS
In addition to intestinal cell-specfic markers (Figure 4), other
control markers were assessed by RT-PCR to evaluate sample
quality of iPSC-derived cells, Caco-2, and primary intestinal
cells (Figure A2). iPSC-derived cells and primary intestinal cells
showed very low expression of pluripotent cell transcription fac-
tor POU domain, class 5 (OCT4) (Nichols et al., 1998), and
about 2000-fold lower than undifferentiated cells (Figure A2A).
To determine how successfully iPSC-derived intestinal cells dif-
ferentiated away from a definitive endoderm cell type after Stage
1, expression of CXCR4 was analyzed. As somewhat expected,
expression of this definitive endoderm marker was highest in
iPSC-derived cells, which went through a definitive endoderm
intermediate at Stage 1, with expression levels ranging about
150-fold higher relative to Caco-2 (Figure A2B). Expression of
the pancreatic foregut marker PDX1 (Miller et al., 1994) was
found to be 10–15-fold higher in iPSC-derived cells and primary
hInEpCs relative to Caco-2 (Figure A2C). Similarly, expression of
the mesenchymal marker Vimentin was also highly upregulated
in primary hInEpCs and iPSC-derived intestinal cells, relative to
Caco-2 (Figure A2D).
Neuronal marker Tubulin, beta 3 (TUBB3) (Poirier et al.,
2010), expression was higher in iPSC-derived cells and primary
hInEpCs relative to Caco-2 (Figure A2E). Expression of cardiac
cell marker Troponin T, type 2 (TNNT2) (Townsend et al., 1994)
was the comparable across intestinal cell types (Figure A2F).
Expression of Paired Box Gene 6 (PAX6), with known roles in
brain development (Mastick et al., 1997), was highly expressed
only Stage 3 iHIOs (Figure A2G).
FIGURE A1 | Additional protein expression data. (A) Isotype controls used for flow cytometry plot gating in Figure 3B. (B) Expression of intestinal
markers E-Cadherin, CDX2, and Villin is shown in primary hInEpC Donors B (top row) and C (bottom row).
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FIGURE A2 | Validation of intestinal cell RT-PCR analysis through
a panel of control/non-intestinal markers. Expression of intestinal
markers was evaluated by RT-PCR in Caco-2, primary hInEpCs
(average of Donors A–C), and iPSC-derived undifferentiated (Undiff),
Stage 3 induced human intestinal organoids (Stg 3 iHIOs), or Stage
3 transwell intestinal cells (Stg 3 TW). Using the DCt method, raw
Ct values were normalized to housekeeping gene RPLP0. N = 3;
Error bars represent SEM.
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FIGURE A3 | All primary hInEpC donors used within the P-glycoprotein
transport assay showed an average lucifer yellow apparent
permeability (Papp) below accepted cutoff for intact monolayers
1.5× 10−6 cm/s. Only transwells that met this cutoff were used to
calculate Papp ratios for Digoxin and Atenolol (Figure 6). N = 3; Error bars
represent SEM.
FIGURE A4 | Intestinal epithelial cell expression of FcRn. (A)
Immunohistochemical analysis demonstrates iPSC-derived Stage 3 intestinal
organoid expression and punctate localization of neonatal Fc Receptor
expression in iPSC-derived organoids. Scale bar, 100μm. (B) Flow cytometry
analysis shows surface FcRn expression on Caco-2 (left) and primary hInEpCs
(right, Donor A shown).
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FIGURE A5 | Not all iPSC lines are capable of producing transwell
intestinal cell monolayers with characteristics suggestive of tight
junction formation. (A) Morphology of during C2128A transwell
differentiation shows that cells lose dense structures during
differentiation; however, the monolayer begins to pull into itself during
late Stage 3 differentiation (arrow heads), resulting in large holes on
transwell inserts. Scale bar, 250μm. (B) C2128A cells do not show
increasing TEER with increasing days in Stage 3 culture. (C) C2128A
shows high FD150 permeability at later stages of differentiation. N = 3;
Error bars represent SEM.
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